Remedies offered to resolve concerns in non-domestic meter reading merger

The CMA is reviewing Macquarie’s proposed legally binding remedy for its acquisition of EAG: selling EAG’s non-domestic, non-smart gas metering business to an approved buyer that can sustain it as a competitor. The regulator found the deal would materially increase concentration in an already concentrated Great Britain market and will assess the remedy over the next 40 working days, including consulting third parties. If the undertakings adequately address its concerns, the CMA will conditionally clear the deal; otherwise, it may refer it for a Phase 2 investigation.

Analysis

The key variable is not whether the CMA accepts a remedy in principle, but whether it approves a buyer able to preserve EAG’s non-smart business as an independent, credible bidder. A thinly capitalized or operationally dependent purchaser could leave customers with fewer effective alternatives and invite further CMA scrutiny; a capable buyer could instead create a more durable challenger. Stark is an imperfect beneficiary because Macquarie retains a minority interest there, while SMS could gain commercial opportunity if the divested unit remains viable. The carve-out is limited to non-domestic, non-smart services, so it does not remove the broader competitive overlap across all metering activities; verify the revenue, contract and asset mix before extrapolating the remedy’s economic significance.

Near term (next several weeks), consultation and purchaser assessment are the catalysts. Conditional clearance would reduce the Phase 2 risk but leave separation and execution questions; rejection or material modification could extend uncertainty and affect the transaction’s timing or economics. Over 6–18 months, the important signal is whether the carved-out business retains customers, operational capability and competitive bidding activity—not simply whether a sale closes. The contrarian point: regulatory progress may be over-read as deal certainty, while the more consequential uncertainty is the quality and independence of the eventual purchaser. No direct listed exposure is established by the supplied identities, so this is a monitoring event rather than a clean standalone trade.

Key Decisions for Investors

• Do not treat the CMA’s willingness to assess undertakings as final clearance. Track the consultation outcome, buyer approval and any changes to the remedy; a Phase 2 referral or prolonged review would falsify the near-term de-risking thesis.
• Monitor Stark and SMS for evidence of customer wins or improved bidding opportunities after the divestiture. Treat any benefit as conditional on the purchaser retaining the people, systems and contracts needed to compete.
• Before taking an event-driven position, verify the transaction’s public-market exposure and the non-smart business’s share of EAG economics, contract duration and standalone operating requirements. Without those data, avoid a deal-arbitrage or sector-proxy trade.
• Over the following 6–18 months, watch customer retention and competitive tender outcomes in the divested segment. A sale that closes but fails to sustain an effective competitor would leave residual regulatory and competition risk.